{ }
001122334455554433221100
001122334455554433221100

UBS raises Carl Zeiss Meditec price target to 55 euros maintaining neutral rating

UBS has increased its price target for Carl Zeiss Meditec from 50 to 55 euros while maintaining a "Neutral" rating. Analyst Graham Doyle noted mixed quarterly results and attributed the new target to expectations of declining capital costs, advising caution for investors.

ubs raises price target for carl zeiss meditec to 55 euros

UBS has increased its price target for Carl Zeiss Meditec from 50 to 55 euros while maintaining a "Neutral" rating. Analyst Graham Doyle noted mixed quarterly results and attributed the new target to expectations of declining capital costs, advising caution for investors.

ubs raises price target for carl zeiss meditec to 55 euros

UBS has increased its price target for Carl Zeiss Meditec from 50 to 55 euros while maintaining a "Neutral" rating. Analyst Graham Doyle noted mixed quarterly results and attributed the new target to expectations of declining capital costs, but indicated there is no immediate reason for a significant upward movement.

ubs maintains neutral rating for carl zeiss meditec with target at 50 euros

UBS has maintained a "Neutral" rating for Carl Zeiss Meditec, setting a target price of 50 euros following the first quarter results. Analyst Graham Doyle highlighted concerns from competitor Staar Surgical regarding a significant decline in demand for refractive ophthalmology in China, which is crucial for Zeiss's annual targets.

UBS maintains neutral rating for Carl Zeiss Meditec with 50 euro target

UBS has maintained a "Neutral" rating for Carl Zeiss Meditec, setting a target price of 50 euros. Analyst Graham Doyle emphasized the need for confidence in the company's recovery, particularly concerning the Chinese market, in his commentary on the European medical technology sector's reporting season.

ubs maintains neutral rating for carl zeiss meditec with target price of 50 euros

UBS has maintained a "Neutral" rating for Carl Zeiss Meditec, setting a target price of 50 euros. Analyst Graham Doyle emphasized the need for confidence in the company's recovery prospects in China, particularly in light of the recent reporting season for the European medical technology sector.

UBS cuts Carl Zeiss Meditec target price to 50 euros citing growth concerns

UBS has reduced its target price for Carl Zeiss Meditec from €65 to €50, maintaining a "Neutral" rating. Analyst Graham Doyle noted that the significant drop in share price over the past year and from 2021 highs is not excessive, as the company is no longer seen as a growth story, particularly with ongoing risks in China.

global retinal laser photocoagulation market poised for significant growth by 2031

The global retinal laser photocoagulation market is projected to exceed USD 349.25 million by 2031, driven by the increasing prevalence of ocular diseases and a growing geriatric population. Key players include Alcon, Ellex Medical, and Carl Zeiss, with advancements in laser technology enhancing treatment precision. However, challenges such as infection risks and stringent regulations may hinder market growth.

Analysts Update Recommendations and Price Targets for Key European Stocks

Analysts have made several notable adjustments to their recommendations and price targets for various companies. Allianz sees a downgrade from Jefferies, while Euronext and Fnac Darty receive upgrades. Kering remains underweight, and UBS Group's rating shifts from Outperform to Neutral. Other companies like Lonza and Soitec also see target price increases.
08:39 13.12.2024

UBS Maintains Neutral Rating on Carl Zeiss Meditec Amid Economic Concerns

UBS has maintained a "Neutral" rating for Carl Zeiss Meditec, setting a price target of 65 euros following the release of fourth-quarter figures. Analyst Graham Doyle noted that the company's 2025 operating profit target is over 10% below market expectations, compounded by management's concerns about a weak economy and consumption pressures in China, which may negatively impact investor sentiment.
10:51 11.12.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.